Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Pyrazole: an Emerging Privileged Scaffold in Drug Discovery | Synapse

November 1, 2023Open Access

Pyrazole: an Emerging Privileged Scaffold in Drug Discovery

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

and vancomycin-resistant enterococci. Here, we discuss the pyrazole-derived drugs reported up to September 2023.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Mohammad A. Alam (Wed,) studied this question.

synapsesocial.com/papers/6a014220581c6e761e780579 https://doi.org/https://doi.org/10.4155/fmc-2023-0207

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections.2014 · 5 citations
2Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole2010 · 57 citations
3Pyrazolopyridine: An efficient pharmacophore in recent drug design and development2022 · 33 citations
4Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease2023 · 10 citations
5Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma2018 · 53 citations